Death of a Drug Class Shows Difficulty of Using Gene Data to Design Drugs

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

This morning, Roche announced that it was stopping all clinical trials of an experimental diabetes drug called aleglitazar because it was not preventing heart attacks and strokes as the company expected, but was causing side effects that reportedly included heart failure, kidney problems, and an increase in fractures.

Hey, check out all the research scientist jobs. Post your resume today!

MORE ON THIS TOPIC